13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03740295 (ClinicalTrials.gov) | October 5, 2018 | 5/10/2018 | Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis | Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis | Multiple Sclerosis | Dietary Supplement: Coconut oil and epigallocatechin gallate;Other: Placebo | Fundación Universidad Católica de Valencia San Vicente Mártir | Valencian Institute of Neurorehabilitation Foundation | Completed | 19 Years | 65 Years | All | 60 | Phase 2 | Spain |
| 2 | NCT00799890 (ClinicalTrials.gov) | May 2009 | 28/11/2008 | Sunphenon in Progressive Forms of Multiple Sclerosis | Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Sunphenon EGCG;Drug: Placebo | Friedemann Paul | TAIYO EUROPE | Completed | 18 Years | 65 Years | All | 61 | Phase 2/Phase 3 | Germany |
| 3 | NCT00525668 (ClinicalTrials.gov) | September 2007 | 4/9/2007 | Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) | Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) | Relapsing-remitting Multiple Sclerosis | Drug: epigallocatechin-gallate (Sunphenon);Drug: placebo | Charite University, Berlin, Germany | NULL | Completed | 18 Years | 60 Years | All | 120 | Phase 1/Phase 2 | Germany |
| 4 | EUCTR2006-006323-39-DE (EUCTR) | 19/06/2007 | 05/03/2007 | Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS | Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS | relapsing-remitting multiple sclerosisICD classification: G35.1 | Product Name: Sunphenon Other descriptive name: Sunphenon EGCg TM | Charité-Universitätsmedizin Berlin | NULL | Not Recruiting | Female: yes Male: yes | 100 | Germany |